David A. Flockhart

22.2k total citations · 5 hit papers
255 papers, 15.3k citations indexed

About

David A. Flockhart is a scholar working on Pharmacology, Genetics and Oncology. According to data from OpenAlex, David A. Flockhart has authored 255 papers receiving a total of 15.3k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Pharmacology, 84 papers in Genetics and 55 papers in Oncology. Recurrent topics in David A. Flockhart's work include Pharmacogenetics and Drug Metabolism (102 papers), Estrogen and related hormone effects (76 papers) and Inflammatory mediators and NSAID effects (30 papers). David A. Flockhart is often cited by papers focused on Pharmacogenetics and Drug Metabolism (102 papers), Estrogen and related hormone effects (76 papers) and Inflammatory mediators and NSAID effects (30 papers). David A. Flockhart collaborates with scholars based in United States, Japan and Canada. David A. Flockhart's co-authors include Zeruesenay Desta, Jackie D. Corbin, James M. Rae, Nadia Soukhova, Todd C. Skaar, Bryan A. Ward, Jae‐Gook Shin, Anne Nguyen, Vered Stearns and X.-J. Zhao and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

David A. Flockhart

250 papers receiving 14.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment

2005 681 citations Zeruesenay Desta, Vered Stearns et al. profile →
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism

2002 669 citations Zeruesenay Desta, Jae‐Gook Shin et al. profile →
Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

2005 567 citations Matthew P. Goetz, James M. Rae et al. Journal of Clinical Oncology profile →
The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity

2003 502 citations David A. Flockhart, Zeruesenay Desta et al. profile →
Studies on the properties and mode of action of the purified regulatory subunit of bovine heart adenosine 3‘:5‘-monophosphate-dependent protein kinase.

1978 412 citations David A. Flockhart et al. profile →

Peers

Countries citing papers authored by David A. Flockhart

Since Specialization

Citations

This map shows the geographic impact of David A. Flockhart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Flockhart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Flockhart more than expected).

Fields of papers citing papers by David A. Flockhart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Flockhart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Flockhart. The network helps show where David A. Flockhart may publish in the future.

Co-authorship network of co-authors of David A. Flockhart

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Flockhart. A scholar is included among the top collaborators of David A. Flockhart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Flockhart. David A. Flockhart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention 2016 ·Dove Medical Press (Taylor and Francis Group) ·Rolf P. Kreutz, Jeffrey A. Breall, Anjan Sinha, (unknown), Richard J. Kovacs, David A. Flockhart	1
2	Pharmacogenomically actionable medications in a safety net health care system 2016 ·PMC ·Janet S. Carpenter, Marc B. Rosenman, Mitchell R. Knisely, Brian S. Decker, Kenneth D. Levy, David A. Flockhart	2
3	A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β 2016 ·Bioorganic & Medicinal Chemistry ·(unknown), (unknown), (unknown), Todd C. Skaar, Joseph Ipe, Wei Lv, David A. Flockhart, Mark Cushman	19
4	Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy 2015 ·Clinical Cancer Research ·Cesar A. Santa‐Maria, Amanda L. Blackford, Anne Nguyen, Todd C. Skaar, Santosh Philips, Steffi Oesterreich, James M. Rae, Zeruesenay Desta, Jason Robarge, N. Lynn Henry, Anna Maria Storniolo, Daniel F. Hayes, Roger S. Blumenthal, Pamela Ouyang, Wendy S. Post, David A. Flockhart, Vered Stearns	18
5	Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention 2013 ·Cancer Discovery ·James N. Ingle, Mohan Liu, D. Lawrence Wickerham, Daniel J. Schaid, Liewei Wang, Taisei Mushiroda, Michiaki Kubo, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Matthew P. Goetz, Matthew M. Ames, Gregory D. Jenkins, Anthony Batzler, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura, Richard M. Weinshilboum	56
6	Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer 2012 ·Journal of Clinical Oncology ·N. Lynn Henry, Faouzi Azzouz, Zereunesay Desta, Lang Li, Anne Nguyen, Suzanne Lemler, Jill A. Hayden, Karineh Tarpinian, (unknown), David A. Flockhart, Vered Stearns, Daniel F. Hayes, Anna Maria Storniolo	284
7	Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics 2012 ·The Pharmacogenomics Journal ·Yuan Ji, (unknown), Scott J. Hebbring, Yubo Chai, G. Douglas Jenkins, (unknown), Karen Snyder, Maureen S. Drews, Zeruesenay Desta, David A. Flockhart, Taisei Mushiroda, Michiaki Kubo, Yoshimasa Nakamura, Naoyuki Kamatani, Daniel J. Schaid, Richard M. Weinshilboum, David A. Mrazek	52
8	The Need for Translational Research on Drug-drug Interactions 2012 ·PMC ·Sean Hennessy, David A. Flockhart	1
9	Tamoxifen Downregulates Ets Oncogene Family Members ETV4 and ETV5 in Benign Breast Tissue: Implications for Durable Risk Reduction 2011 ·Cancer Prevention Research ·(unknown), Dawei Bu, (unknown), Venetia Sarode, Raheela Ashfaq, Kelly K. Hunt, Weiya Xia, Joyce O’Shaughnessy, Michael D. Grant, Banu Arun, William C. Dooley, Alexander Miller, David A. Flockhart, Cheryl Lewis	13
10	Estrogen Receptor Genotypes, Menopausal Status, and the Effects of Tamoxifen on Lipid Levels: Revised and Updated Results 2010 ·Clinical Pharmacology & Therapeutics ·Daniel F. Hayes, Todd C. Skaar, James M. Rae, N. Lynn Henry, Anne Nguyen, Vered Stearns, (unknown), Santosh Philips, Zeruesenay Desta, David A. Flockhart	12
11	Pharmacotherapy and pregnancy: Highlights from the first International Conference for Individualized Pharmacotherapy in Pregnancy 2009 ·PMC ·David M. Haas, Jamie L. Renbarger, Scott C. Denne, Mahmoud Ahmed, Thomas R. Easterling, (unknown), Eric M. Meslin, Gideon Koren, Anne Zajicek, Wayne R. Snodgrass, David A. Flockhart	7
12	Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity 2009 ·Pharmacogenetics and Genomics ·Million Arefayene, Santosh Philips, (unknown), (unknown), Zeruesenay Desta, David A. Flockhart, David S. Wilkes, Todd C. Skaar	31
13	Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100 2008 ·Journal of Clinical Oncology ·Bryan P. Schneider, Μolin Wang, Milan Radovich, George W. Sledge, Sunil Badve, Ann D. Thor, David A. Flockhart, Bradley A. Hancock, Nancy E. Davidson, Julie R. Gralow, Maura N. Dickler, Edith A. Perez, Melody Cobleigh, Tamara Shenkier, Susan M. Edgerton, Kathy D. Miller	487
14	Drug Interactions and Pharmacogenomics in the Treatment of Breast Cancer and Depression 2008 ·American Journal of Psychiatry ·N. Lynn Henry, Vered Stearns, David A. Flockhart, Daniel F. Hayes, Michelle Riba	64
15	Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes 2006 ·Breast Cancer Research and Treatment ·Bryan P. Schneider, Todd C. Skaar, George W. Sledge, Sunil Badve, Lang Li, David A. Flockhart	21
16	Thiotepa is a specific inhibitor of cytochrome P450 2B6 Implications for cyclophosphamide metabolism 2002 ·Clinical Pharmacology & Therapeutics ·James M. Rae, (unknown), Nadia Soukhova, David A. Flockhart	1
17	Pharmacokinetics of Fluvoxamine in Relation to CYP2C19 Phenotype and Genotype 2002 ·Drug metabolism and drug interactions ·(unknown), Troy L. ZumBrunnen, (unknown), Chad M. VanDenBerg, Hardik Dineshbhai Desai, D.J. Weidler, David A. Flockhart	11
18	Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans 2002 ·Pharmacogenetics ·Ji‐Hong Shon, Young-Ran Yoon, Kyoung‐Ah Kim, (unknown), (unknown), Ji Young Park, (unknown), David A. Flockhart, Jae‐Gook Shin	71
19	Coprescription of paroxetine with tamoxifen to reduce hot flashes reduced plasma 4-hydroxy-N-desmethyl-tamoxifen plasma concentrations in a CYP2D6-dependent manner 2001 ·Clinical Pharmacology & Therapeutics ·David A. Flockhart, Daniel F. Hayes, James M. Rae, Pankaj Bhargava, (unknown), Vered Stearns	1
20	Effect of CYP3A inhibition on vesnarinone metabolism in humans* 1998 ·Clinical Pharmacology & Therapeutics ·(unknown), Chim C. Lang, (unknown), (unknown), (unknown), David A. Flockhart, (unknown)	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact